Promising Results for Experimental Fatty Liver Drugs
A two-phase study demonstrated that the two experimental drugs—one containing "Zabopygdutide," a GLP-1 class medication, and the other a drug that promotes the death of damaged cells—showed promising results in treating fatty liver disease. After 12 weeks of treatment, there were clear signs of improvement in liver tissue, followed by a significant reduction in liver fat and damage after 48 weeks compared to the placebo group. The researchers confirmed that the improvement in liver health occurred independently of weight loss, with direct benefits to the liver observed even in individuals who lost less than 5% of their body weight.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)